What are the treatment options for hypothalamic obesity?

Obesity is a medical condition characterized by excessive amounts of adipose tissue, also known as fat tissue. To be diagnosed with obesity, a person will have a body mass index (BMI) of 30 or above. BMI is calculated using a person's height and weight. Though not a perfect metric, BMI remains a useful screening method for overweight and obesity. A healthcare provider will often use additional tests and techniques during a diagnosis.

Obesity is the result of an imbalance of calories consumed and energy expended, which leads to excess weight gain and excess adipose tissue. There are many factors that influence obesity, such as genetics, where a person lives, and underlying medical conditions.

Hypothalamic obesity is a type of obesity caused by damage to the hypothalamus, a part of the brain that acts as a control center for many different functions, including sleep-wake cycles, circadian rhythms (the body's internal clock), hormone production, thirst, hunger, and metabolism.

For people with hypothalamic obesity, the hypothalamus is damaged in a way that disrupts the hormonal and neurological signals that regulate hunger and fullness (satiety). As a result, a person experiences polyphagia or hyperphagia—extreme and overwhelming hunger. Damage to the hypothalamus also disrupts metabolism, slowing the pace at which the body uses energy. Weight gain can occur quickly.

While obesity ranks as one of the most common medical conditions in many countries throughout the world, hypothalamic obesity is much less common. While treatments for non-hypothalamic obesity and hypothalamic obesity can overlap, hypothalamic obesity is considered a unique medical condition with unique challenges for treatment.

How is hypothalamic obesity treated?

Hypothalamic obesity requires individualized care that takes into account underlying causes, complications, coexisting medical conditions, and a person’s unique needs. People with hypothalamic obesity are best treated by a multidisciplinary team made up of healthcare providers with different specialties.

Obesity medications

Treatment options for obesity in general have expanded in recent years, with the approval of several medications, including GLP-1 agonist medications. While the effectiveness of these medications in treating hypothalamic obesity is still being studied, a healthcare provider may recommend this medication.

Hormone replacement

One of the main functions of the hypothalamus is to regulate the activity of the pituitary gland. Located just below the hypothalamus and roughly the size of a pea, the pituitary gland is sometimes called the "master gland" because it regulates activity for most of the hormone producing glands in the body.

Damage to the hypothalamus usually means the pituitary gland isn’t functioning normally, and people with hypothalamic obesity often have low or imbalanced levels of pituitary hormones. This creates hormone imbalances that contribute to weight gain. Medications to replace pituitary hormones are typically a part of treatment.

Diet and exercise

While hypothalamic obesity usually does not respond to lifestyle interventions like diet and exercise, diet and exercise can be an important part of treatment. It's recommended to work with a registered dietitian to develop an eating plan that supports treatment. Good nutrition and physical activity also promote good overall health, including mental health.

Mental health and social support

Hypothalamic obesity is not an easy condition to live with, and it can have a significant impact on many aspects of a person's life, including mental health and relationships. Counselors, mental health professionals, and social support can be valuable in helping individuals and families cope with hypothalamic obesity.

New and emerging therapies

There are currently no therapies approved specifically for hypothalamic obesity and research into treating hypothalamic obesity is ongoing. As mentioned above, GLP-1 agonist medications are being studied in the treatment of hypothalamic obesity.

A medication that acts on the melanocortin 4 receptor (MC4R) pathway is in clinical trials. A pathway is a sequence of actions that occur at the molecular level. The MC4R pathway is a sequence of events that occur within the hypothalamus. It plays a critical role in the regulation of hunger, appetite, and energy expenditure. This medication is already approved for the treatment of rare genetic disorders of obesity.

Even with new and emerging treatments, individualized care will remain an important focus. Hypothalamic obesity affects different people in different ways. A goal of research is to better understand how the condition varies from person to person, and to better identify what treatments will work for an individual.

Your best source of information about your treatment options will be a healthcare provider.